Lanthanum Carbonate
Brand names: Fosrenol
Lanthanum carbonate is a calcium-free, aluminium-free phosphate binder used to control hyperphosphataemia in chronic kidney disease, particularly in dialysis patients.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
In the gastrointestinal tract lanthanum binds dietary phosphate to form insoluble, poorly absorbed lanthanum phosphate, reducing phosphate absorption.
Prescribing in practice
- Tablets must be chewed thoroughly and taken with or immediately after food to bind phosphate effectively and reduce the risk of gastrointestinal obstruction.
- Gastrointestinal effects, and rarely bowel obstruction, perforation or ileus, can occur, so use caution in patients with gut motility disorders.
- Separate administration from other oral medicines whose absorption may be impaired by binders.
Monitoring
Monitor serum phosphate, and calcium, to guide dose titration to target while avoiding over-suppression.
Counselling the patient
- Always chew the tablets fully and take them with food, never on an empty stomach.
- Report persistent constipation, severe abdominal pain or vomiting.
- Take other tablets at a different time from your phosphate binder as advised.
Evidence & guidelines
Renal mineral and bone guidance supports phosphate binders such as lanthanum carbonate for managing hyperphosphataemia in CKD.
Reference: KDIGO CKD-MBD Clinical Practice Guideline Update 2017; Hutchison et al. NDT 2005 (lanthanum phase III); MHRA SPC Fosrenol; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- HIV Opportunistic Infection Risk (CD4-Based) · HIV / Immunodeficiency
- Corrected Calcium · Electrolytes
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019